Medigene AG (XETRA: MDG1.DE) AI-Powered Stock Analysis
See how Medigene AG scores across key metrics like financial growth, valuation, and market position on the XETRA, using AI-driven evaluation.
MDG1.DE●XETRA
HealthcareBiotechnology
€0.13
€0.05(27.64%)
German Market opens in 21h 2m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerMedigene AG (XETRA: MDG1.DE) Stock Overall Grade
Medigene AG's grade for its XETRA listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Medigene AG's overall XETRA stock rating.
Forecast
C+Score
50/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Medigene AG (XETRA: MDG1.DE) AI-Powered Stock Analysis
On the XETRA, MDG1.DE demonstrates Normal performance with an overall Forecast Score of 50/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), the XETRA-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(XETRA: MDG1.DE) Component Analysis Explained
Understand the key factors behind each Medigene AG (XETRA: MDG1.DE) stock grade, including financials, comparisons, and forecasts.